CancerGuide Analysis
As an integrative CancerGuide, I view my role as that of a researcher, information provider, support-person, patient advocate, and co-developer, with the patient and her physicians, of an integrative treatment plan. Such a plan can rationally encompass medical oncology treatments, nutrition, nutritional supplements, traditional medical systems, body care, and mind-body care. The blend of these therapies must meet the patient's needs and reflect his or her healing philosophy, encourage synergies among varying treatments, avoid untoward interactions between (and among) allopathic and complementary treatments, and be realistically designed so it can be sustained by the patient. As a nonphysician Cancer Guide, I do not recommend therapies and I encourage patients to discuss all of their treatment options and ongoing complementary modalities with their oncologists, other physicians, and complementary care providers. I do refer patients to leading surgical, medical, and radiation oncologists; integrative oncologists and cancer specialists; and a range of reputable complementary care providers.
In this case presentation of a 51-year-old woman with lobular carcinoma metastatic to the bone, I would encourage the patient to seek at least one if not more opinions from leading innovative medical oncologists who specialize in breast cancer, and I could provide her with a list of potential therapeutic options, based upon my working knowledge and research, to present to these physicians for discussion. I would also encourage her to seek the overall guidance of an integrative cancer specialist (exemplified by physicians at the Block Center for Integrative Cancer Care Given her relatively young age and reasonable performance status, despite fatigue and decreasing appetite, it may be an appropriate time for this patient to consider chemotherapy options, along with complementary nutrition and mind-body medicine, in an effort to forestall rapid disease progression while other cutting-edge conventional options are investigated. Whether she should continue taking an aromatase inhibitor, perhaps switching to another agent such as anastrozole (Arimidex), remains an open question she should discuss with her oncologist. I would let the patient know that her Aredia may not only help her with skeletal morbidity, but preliminary evidence indicates that bisphosphonates may prolong survival, although this needs to be confirmed in controlled clinical trials. 1, 2 An ideally rational approach to chemotherapy would be the use of a chemotherapy sensitivity assay, specifically the ex vivo apoptotic (EVA) assay used by oncologist Robert Nagourney to determine a singleagent or polychemotherapy regimen that would afford her the optimal chance of response. The EVA test has proven to have predictive value, unlike previous clonogenic or H-3 thymidine assays. 3 However, the patient's metastases, which appear limited to bone, would not likely yield a surgically accessible and sufficiently sizable tumor sample necessary for the EVA assay. If an EVA assay is impossible, I would discuss with the patient my research on a range of chemotherapy options that she may wish to discuss with her oncologist. My goal is never to second-guess medical professionals but rather to enable patients to be properly informed so they make the best use of their (often limited) time with busy oncologists in the world of managed care medicine. In this patient's case, because she has not had prior treatment with taxanes, I would mention paclitaxel and docetaxel, and discuss the current state of research on these and other agents, including capecitabine, gemcitabine, and vinorelbine, and the potential value of combination drug regimens.
4-6
A critically important question is whether the patient's breast cancer overexpresses Her-2/neu. If so, she could be a candidate for treatment with the monoclonal antibody Herceptin, along with chemotherapy. In a major study published in the New England Journal of Medicine, the combination of Herceptin and standard chemotherapy (an anthra-cycline or paclitaxel) produced a 50% response rate and a median survival of 25.1 months, which was significantly better than chemotherapy alone. 7 As the patient pursues chemotherapeutic options, I would recommend that she investigate with her physician some experimental treatments currently being tested in the National Cancer Institute and/or proprietary clinical trials. Among the promising treatments in the pipeline are vaccines and antibodies (Theratope; APC 8024 dendritic cell vaccine; CEAscan), differentiation agents (Targretin) antiangiogenic agents (2-Methoxyestrodial, Anti-VEGF, Marimastat, IM862), and signal transduction inhibitors (R115777, CCI-779). I would explain to the patient that one way to sustain hope would be to view her current conventional and complementary treatment plan as a bridge she can traverse to keep her healthy, although probably not cancer-free, until new, more effective treatment options become available through clinical trials or FDA approval.
In the complementary realm, I would talk to the patient about her diet, which may lack sufficient sources of health-promoting and immune-augmenting protein (legumes, beans, fish), fruits, and grains. I would refer her for further refinement to nutritionists or naturopaths specializing in anticancer diets. She appears to lack sufficient sources of omega-3 fatty acids, which promote immune competence, reduce oxidative stress, and inhibit angiogenesis among other anticancer actions, which would call for a stable fish oil supplement in addition to more fish in her diet. Her decreasing appetite is a concern, so I would inform her about the agent hydrazine sulfate, which has shown some efficacy in improving appetite, relieving pain, and slowing cachexia in advanced cancer patients, 8 and suggest that she discuss it with her integrative care provider.
Although her supplements would be included in an integrative nutrition program for most cancers, there are many opportunities missed for supplements that could both enhance the efficacy of her chemotherapy and provide other significant anticancer benefits. I would evaluate her combination supplements with which I am unfamiliar, including Primal Defense G-132. Then, if the following nutrients are not present in her current regimen, I would suggest that she discuss them with her integrative care provider and/or oncologist: Curcumin (protein tyrosine kinase inhibitor, anti-angiogenic, pro-apoptotic, COX-2 inhibitor), resveratrol (differentiator, protein tyrosine kinase inhibitor, COX-2 inhibitor), astragulus (immune potentiator), mushroom extracts including maitake, shitake, reishi, and coriolus versicolor (immune enhancers), calcium d-glucarate (promotes glucaronidation of excess estrogens by the liver), green tea extract (antioxidant, protein tyrosine kinase inhibitor, anti-angiogenic, COX-2 inhibitor), n-acetyl cysteine (glutathione precursor, antioxidant, and detoxifier that may be contraindicated with platinum-based or alkylating chemotherapies); rosemary extract (antioxidant, anti-angiogenic, COX-2 inhibitor); melatonin (antioxidant, immune stimulant); whey protein (helps sustain gastointestinal health during toxic therapies, detoxifier); modified citrus pectin (inhibitor of metastases), and L-glutamine as well as probiotics to sustain gastrointestinal health and uphold immune functions during toxic chemotherapy.
The need for immune enhancement via supplementation is justified not only by the patient's progressive metastatic disease, but by the results of her immune tests indicating low percentages of CD3 Tcells and CD4 helper T-cells, and a CD4/CD8 ratio on the low end of the reference range. These findings suggest a suboptimal cellular immunity, and supplements including Vitamins C and E, NAC, glutathione, melatonin, astragulus, and mushroom extracts may improve these indices. 9 Further adjustments and refinements to diet and supplementation should be made by an integrative cancer specialist or nutritionist as guided by test results on nutrient, oxidative, and immune status. Such a provider could also help tailor diet and supplements to optimally reduce the side effects of any radiation or chemotherapy treatments.
I would advise her to be cautious about over-use of soy products or supplements, which could act as estrogenic stimulants, although this concern is based on preclinical research and remains theoretical. I would advise her to be careful about nutrients that act as blood thinners-Vitamin E, ginger, ginkgo biloba, green tea, and garlic-while on chemotherapy that may cause thrombocytopenia. The patient and her doctor should monitor platelet levels with an awareness that she is taking blood-thinning nutrients and should discontinue them if and when her platelets are significantly reduced. Ideally, an integrative cancer specialist fully aware of drug-nutrient interactions would help her design a supplement program that is both safe and effective.
Several off-label agents could be discussed with her physician. A recent review paper by Andrew Dannenberg and his colleagues at New York Hospital-Cornell Medical Center has underscored the potential of selective COX-2 (cyclooxygenase) inhibitors in breast cancer. 10 The COX-2 enzyme is overexpressed in many breast cancers; NSAIDS that inhibit COX-2 have been shown to reduce breast cancer risk in epidemiologic studies; and the selective COX-2 inhibitor celecoxib has caused dramatic regression of mammary tumors in animal studies. 10 The mechanisms include downregulation of inflammatory and tumor-promoting prostaglandins, and anti-angiogenic activity. Thus, the patient's use of rofecoxib (Vioxx ® ) for pain may be continued with some antitumor effects, although she may consider a switch to celecoxib (Celebrex ® ), since most breast cancer research has involved this agent, along with dosing at levels higher than standard for arthritis (600-800 mg vs 400 mg/day). Another off-label agent is the opioid antagonist naltrexone, given in a low dose at bedtime, which investigator Bernard Bihari has demonstrated to have antitumor activity, based on putative opioid and immune modulation in an extensive case series. 11 Finally, reduction of serum copper through use of copper chelators has been demonstrated to be a viable anti-angiogenic strategy, because copper is a cofactor in many angiogenic pathways. 12 A phase I trial has shown disease stabilization in patients with advanced cancer who took the copper chelator tetrathiomolybdate (TM) and achieved target serum copper levels. 13 TM could be an option for this patient, although it should not be taken during chemotherapy since in combination with myelotoxic agents it can cause cytopenias.
The patient's increasing physical pain compromises her quality of life and probably her emotional well-being. I would refer her to a radiation oncologist specializing in bone metastases to determine whether external beam radiation or radionuclide therapy would help relieve her pelvic bone pain. I would also refer her to a specialist in cancer pain management and, if one were not available in her area, I would suggest that she travel to a nearby Comprehensive Cancer Center for consultation with one. (Despite some notable progress, cancer pain is still notoriously undertreated.)
With regard to the patient's psychosocial status, I would ask whether she felt she had all of the psychosocial support she needs, and explore areas for enhancement. Fortunately, she has the support of a loving husband, but I would ask about his stress levels and whether she also has friends and other family members to turn to for guidance and sharing. A question would be raised in my mind regarding her optimism and apparent lack of distress in the face of metastatic disease. (A number of studies have associated an expressive coping style, including awareness and expression of emotional distress in response to a cancer diagnosis, with a better medical prognosis.) 14 Is she a good coper who has found a sense of peace and acceptance regarding her condition, or is she keeping a raft of negative emotions at bay? I would gently explore this issue, and if she felt that she would benefit from psychotherapy, I'd recommend a therapist skilled at treating cancer patients. I would also raise the idea of joining a psychosocial support group along the lines of Stanford psychiatrist David Spiegel's supportive-expressive therapy, which in one study has shown a significant survival advantage for patients with metastatic breast cancer and which has consistently shown psychosocial benefits. 15, 16 Although her use of tapes for relaxation and imagery can only be helpful, I would help her identify a mind-body practitioner capable not only of teaching mind-body skills but of guiding her with counseling, cognitive-behavioral methods, and exercises (eg, expressive writing) to help her manage the stress associated with her finances, work, and the illness itself. (Ideally, this professional could fulfill both psychotherapist and mind-body clinician roles.) If she were interested, I would refer her to a bodywork practitioner who used either bioenergetics, craniosacral work, acupressure, or somato-emotional release to help her integrate emotional experience. Such a bodyworker or acupuncturist could address the underlying energy (Qi) stagnation evident in her TCM diagnostic workup. If she was open to such a discussion, I would also inquire about her spiritual or religious life, 17 because spiritual practice has been shown to help maintain wellness, and because it offers the prospect of a deeper healing even in the absence of physical cure.
Although her integrative treatment plan would be challenging and at times complex, she would be aided greatly by the guidance of her integrative "team," which would ideally include a medical oncologist, integrative care specialist, nutritionist, bodyworker, psychotherapist and/or mind-body clinician. In my role as Cancer Guide, I would refer her to some of these providers; offer research enabling her to make informed decisions in partnership with these providers; collaborate with her to make sure that her treatment plan reflects her goals, needs, and values; help her to focus and simplify her choices so they don't become overwhelming; and offer my advocacy and emotional support whenever it is needed.
Although this patient's condition is quite serious, I would communicate my belief that such a multileveled, integrative treatment plan offers the promise of disease stabilization or regression, which could conceivably prolong her survival and enable her, eventually, to benefit from one (or more) of the experimental cancer therapies currently being tested. I would speak to her of "hope without illusions," a more realistic and compassionate approach than the still fashionable preoccupation in medical circles with "false hope."
